# Avexitide

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/avexitide
Canonical HTML page: https://gethealthbrief.com/entity/avexitide

## Recent coverage (1 stories)

### Amylyx Cuts Low Blood Sugar Episodes 55% After Bariatric Surgery
2026-08-18 22:32:01 · Sentiment: Positive · Impact: 6/10 · Sources: 2

A late-stage trial found Amylyx's once-daily injection avexitide reduced hypoglycemic episodes by 55% in people with post-bariatric hypoglycemia, a condition with no approved treatments. The drug was well tolerated, and the company plans a U.S. filing by end of 2026. For health systems and clinicians, the result signals a potential first-ever standard therapy that could change post-bariatric care.
Full story: https://gethealthbrief.com/story/amylyx-avexitide-post-bariatric-hypoglycemia-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.